The US FDA recently approved ceftaroline fosamil (ceftaroline) for the treatment of acute bacterial skin and soft structure infections (ABSSSIs) and community-acquired pneumonia. In 2010 ...

Clinical trials conducted in patients with CAP treated on an outpatient basis provide relevant data for clinicians dealing with management of this common serious infection. A number of trials have ...

The COVID-19 pandemic underscored bacterial resistance as a critical global health issue, exacerbated by the increased use of antibiotics during the crisis. Notwithstanding the pandemic’s prevalence, ...